Metastatic kidney cancer prognosis — what living with advanced disease actually looks like

It tells you what happened to large groups of people treated in the past, often years before the treatments now in use. It does not tell you what will happen to you. A prognosis is built from averages, and averages hide an enormous spread: within the same risk group, some people progress quickly and others stay stable for a long time. Your own outlook depends on your risk group, how many sites are involved and which ones, how the disease behaves over the first few scans, your kidney function and general fitness, and how well you tolerate systemic treatment. Ask your oncologist what your own scans and blood tests are showing rather than reading a figure written for a population.

There is no single honest number, and we do not publish one. Advanced kidney cancer behaves very differently from person to person: some disease sits almost still for long periods, some moves quickly, and the range hidden inside every published figure is wide. Survival statistics also lag behind practice, because they describe people treated before the current immunotherapy and targeted classes were in routine use. What is more useful than a figure is the pattern your own disease shows over the first few months of treatment, together with your risk group and how you are feeling day to day. Bring the question to a medical oncologist who has read your scans and reports.

For most people, advanced kidney cancer is managed as a long-term condition rather than cured. The aim is to control the disease, protect how you feel, and keep you living your life. A smaller number of people do have deep and lasting responses to immune-based treatment. Where only one or two deposits are present, adding local treatment such as stereotactic radiation, or surgery coordinated with specialist partners, is sometimes discussed with the intention of a long disease-free interval. Nobody can promise either outcome in advance, and you should be wary of anyone who does. What your team can do is set a realistic aim with you and revisit it at every scan.

It is one of several things that matter. As a group, disease confined to the lungs tends to behave less aggressively than disease in the liver, bone or brain, and the number of sites involved carries weight too. The site is never read alone, though. How soon the spread appeared after the original diagnosis, what your routine blood tests show, how well you are managing daily activities, and how the disease answers the first line of treatment all feed into the same picture. Sites that are causing symptoms, such as a painful bone deposit, may also be treated directly with radiation while systemic treatment continues.

Because in advanced kidney cancer, the choice of which class of systemic treatment to start is guided by a risk grouping rather than by the stage alone. The grouping is built from simple things: how long it was between diagnosis and needing systemic treatment, how well you are managing daily activities, and a handful of routine blood results including haemoglobin, calcium, neutrophils and platelets. Those place the disease in a favourable, intermediate or poor risk group, and NCCN-based guidance links the group to the treatment classes that are reasonable to start with. It is a planning tool, not a prediction about you, and it can change over time.

It is expected, and it is planned for. Scans are repeated at set intervals precisely so that a change is picked up early, while you still have options and still feel well. If the disease starts moving again, treatment is usually switched to a different class rather than abandoned: if you began on an immune-based combination, a VEGF TKI or an mTOR inhibitor may follow, and the reverse also happens. Where only one site is progressing, that site may be treated with radiation while the rest of the plan continues unchanged. Every switch at CION goes back to the tumour board, and your kidney function, side effects and preferences are part of the decision.